Can MRGPRX2 inhibition prevent migraine? Evommune’s EVO756 enters Phase 2b study
Evommune begins a Phase 2b EVO756 migraine trial after a urticaria setback, testing whether MRGPRX2 inhibition can deliver preventive benefit.
Pharma & Biotech
Pharma & Biotech
Is this the migraine breakthrough Big Pharma missed? Kallyope’s elismetrep hints at a whole new treatment playbook
Kallyope’s elismetrep migraine data point to a new TRPM8 treatment pathway. Find out what Phase 3 could prove next.
Pharma & Biotech
Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.